180 related articles for article (PubMed ID: 25558828)
21. Human pancreatic cancer tumors are nutrient poor and tumor cells actively scavenge extracellular protein.
Kamphorst JJ; Nofal M; Commisso C; Hackett SR; Lu W; Grabocka E; Vander Heiden MG; Miller G; Drebin JA; Bar-Sagi D; Thompson CB; Rabinowitz JD
Cancer Res; 2015 Feb; 75(3):544-53. PubMed ID: 25644265
[TBL] [Abstract][Full Text] [Related]
22. A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial.
Fuchs CS; Azevedo S; Okusaka T; Van Laethem JL; Lipton LR; Riess H; Szczylik C; Moore MJ; Peeters M; Bodoky G; Ikeda M; Melichar B; Nemecek R; Ohkawa S; Świeboda-Sadlej A; Tjulandin SA; Van Cutsem E; Loberg R; Haddad V; Gansert JL; Bach BA; Carrato A
Ann Oncol; 2015 May; 26(5):921-927. PubMed ID: 25609246
[TBL] [Abstract][Full Text] [Related]
23. NAMPT inhibition sensitizes pancreatic adenocarcinoma cells to tumor-selective, PAR-independent metabolic catastrophe and cell death induced by β-lapachone.
Moore Z; Chakrabarti G; Luo X; Ali A; Hu Z; Fattah FJ; Vemireddy R; DeBerardinis RJ; Brekken RA; Boothman DA
Cell Death Dis; 2015 Jan; 6(1):e1599. PubMed ID: 25590809
[TBL] [Abstract][Full Text] [Related]
24. The conflicting roles of tumor stroma in pancreatic cancer and their contribution to the failure of clinical trials: a systematic review and critical appraisal.
Bijlsma MF; van Laarhoven HW
Cancer Metastasis Rev; 2015 Mar; 34(1):97-114. PubMed ID: 25566685
[TBL] [Abstract][Full Text] [Related]
25. Cross-species antibody microarray interrogation identifies a 3-protein panel of plasma biomarkers for early diagnosis of pancreas cancer.
Mirus JE; Zhang Y; Li CI; Lokshin AE; Prentice RL; Hingorani SR; Lampe PD
Clin Cancer Res; 2015 Apr; 21(7):1764-71. PubMed ID: 25589628
[TBL] [Abstract][Full Text] [Related]
26. Cytidine deaminase polymorphism predicts toxicity of gemcitabine-based chemotherapy.
Ding X; Chen W; Fan H; Zhu B
Gene; 2015 Mar; 559(1):31-7. PubMed ID: 25582275
[TBL] [Abstract][Full Text] [Related]
27. Expression of oncogenic HMGN5 increases the sensitivity of prostate cancer cells to gemcitabine.
Guo Z; Zhang X; Li X; Xie F; Su B; Zhang M; Zhou L
Oncol Rep; 2015 Mar; 33(3):1519-25. PubMed ID: 25572120
[TBL] [Abstract][Full Text] [Related]
28. Screening analysis of ubiquitin ligases reveals G2E3 as a potential target for chemosensitizing cancer cells.
Schmidt F; Kunze M; Loock AC; Dobbelstein M
Oncotarget; 2015 Jan; 6(2):617-32. PubMed ID: 25593194
[TBL] [Abstract][Full Text] [Related]
29. Orchestrating the Tumor Microenvironment to Improve Survival for Patients With Pancreatic Cancer: Normalization, Not Destruction.
Whatcott CJ; Han H; Von Hoff DD
Cancer J; 2015; 21(4):299-306. PubMed ID: 26222082
[TBL] [Abstract][Full Text] [Related]
30. Genomic profiling guides the choice of molecular targeted therapy of pancreatic cancer.
Frank TS; Sun X; Zhang Y; Yang J; Fisher WE; Gingras MC; Li M
Cancer Lett; 2015 Jul; 363(1):1-6. PubMed ID: 25890222
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of CD47 Effectively Targets Pancreatic Cancer Stem Cells via Dual Mechanisms.
Cioffi M; Trabulo S; Hidalgo M; Costello E; Greenhalf W; Erkan M; Kleeff J; Sainz B; Heeschen C
Clin Cancer Res; 2015 May; 21(10):2325-37. PubMed ID: 25717063
[TBL] [Abstract][Full Text] [Related]
32. Pancreatic cancer-associated diabetes is an "exosomopathy".
Korc M
Clin Cancer Res; 2015 Apr; 21(7):1508-10. PubMed ID: 25645860
[TBL] [Abstract][Full Text] [Related]
33. Down-regulation of miR-223 reverses epithelial-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells.
Ma J; Fang B; Zeng F; Ma C; Pang H; Cheng L; Shi Y; Wang H; Yin B; Xia J; Wang Z
Oncotarget; 2015 Jan; 6(3):1740-9. PubMed ID: 25638153
[TBL] [Abstract][Full Text] [Related]
34. ADAM8 as a drug target in pancreatic cancer.
Schlomann U; Koller G; Conrad C; Ferdous T; Golfi P; Garcia AM; Höfling S; Parsons M; Costa P; Soper R; Bossard M; Hagemann T; Roshani R; Sewald N; Ketchem RR; Moss ML; Rasmussen FH; Miller MA; Lauffenburger DA; Tuveson DA; Nimsky C; Bartsch JW
Nat Commun; 2015 Jan; 6():6175. PubMed ID: 25629724
[TBL] [Abstract][Full Text] [Related]
35. Gemcitabine, oxaliplatin, and capecitabine (GEMOXEL) compared with gemcitabine alone in metastatic pancreatic cancer: a randomized phase II study.
Petrioli R; Roviello G; Fiaschi AI; Laera L; Marrelli D; Roviello F; Francini E
Cancer Chemother Pharmacol; 2015 Apr; 75(4):683-90. PubMed ID: 25618415
[TBL] [Abstract][Full Text] [Related]
36. Ratio of phosphorylated HSP27 to nonphosphorylated HSP27 biphasically acts as a determinant of cellular fate in gemcitabine-resistant pancreatic cancer cells.
Kang D; Choi HJ; Kang S; Kim SY; Hwang YS; Je S; Han Z; Kim JH; Song JJ
Cell Signal; 2015 Apr; 27(4):807-17. PubMed ID: 25615626
[TBL] [Abstract][Full Text] [Related]
37. Histopathological effects of preoperative chemoradiotherapy for pancreatic cancer: an analysis for the impact of radiation and gemcitabine doses.
Hirata T; Teshima T; Nishiyama K; Ogawa K; Otani K; Kawaguchi Y; Konishi K; Tomita Y; Takahashi H; Ohigashi H; Ishikawa O
Radiother Oncol; 2015 Jan; 114(1):122-7. PubMed ID: 25614389
[TBL] [Abstract][Full Text] [Related]
38. A genome-wide investigation of microRNA expression identifies biologically-meaningful microRNAs that distinguish between high-risk and low-risk intraductal papillary mucinous neoplasms of the pancreas.
Permuth-Wey J; Chen YA; Fisher K; McCarthy S; Qu X; Lloyd MC; Kasprzak A; Fournier M; Williams VL; Ghia KM; Yoder SJ; Hall L; Georgeades C; Olaoye F; Husain K; Springett GM; Chen DT; Yeatman T; Centeno BA; Klapman J; Coppola D; Malafa M
PLoS One; 2015; 10(1):e0116869. PubMed ID: 25607660
[TBL] [Abstract][Full Text] [Related]
39. First-in-man phase 1 clinical trial of gene therapy for advanced pancreatic cancer: safety, biodistribution, and preliminary clinical findings.
Buscail L; Bournet B; Vernejoul F; Cambois G; Lulka H; Hanoun N; Dufresne M; Meulle A; Vignolle-Vidoni A; Ligat L; Saint-Laurent N; Pont F; Dejean S; Gayral M; Martins F; Torrisani J; Barbey O; Gross F; Guimbaud R; Otal P; Lopez F; Tiraby G; Cordelier P
Mol Ther; 2015 Apr; 23(4):779-89. PubMed ID: 25586689
[TBL] [Abstract][Full Text] [Related]
40. Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer.
Le DT; Wang-Gillam A; Picozzi V; Greten TF; Crocenzi T; Springett G; Morse M; Zeh H; Cohen D; Fine RL; Onners B; Uram JN; Laheru DA; Lutz ER; Solt S; Murphy AL; Skoble J; Lemmens E; Grous J; Dubensky T; Brockstedt DG; Jaffee EM
J Clin Oncol; 2015 Apr; 33(12):1325-33. PubMed ID: 25584002
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
